PACCAR (PCAR) rated new Overweight at Piper. $48.50 price target. Best positioned to benefit from a return to growth in the North American truck market.
Pier 1 Imports (PIR) rated new Buy at Deutsche. $25 price target. Company is leveraged to positive industry trends.
Progressive (PRGS) downgraded at Mizuho from Buy to Neutral, Mizuho said. $14.50 price target. Company is losing a key leader, which it will struggle to replace.
Pioneer Natural (PXD) rated new Outperform at Wells. Wolfcamp play should drive near-term growth.Questcor Pharmaceuticals (QCOR) upgraded at Jefferies to Buy from Hold, Jefferies said. $28 price target. Limited downside with improved visibility. Vertex Pharmaceuticals (VRTX) rated new Buy at Deutsche. $77 price target. New cystic fibrosis drug should be the next main driver.
STOCK COMMENTS / EPS CHANGESMoody's (MCO) estimates, target increased at Piper. MCO estimates were raised through 2013, Piper Jaffray said. Company is leveraged to higher debt issuance rates. Overweight rating and new $55 price target. Pentair (PNR) estimates, target raised at Credit Suisse. Shares of PNR now seen reaching $54, according to Credit Suisse. Estimates also increased, as the Tyco deal should add to earnings. Neutral rating. Riverbed (RVBD) estimates, target boosted at ThinkEquity. Shares of RVBD now seen reaching $26, according to ThinkEquity. Estimates also upped, given higher expected demand and pricing. Buy rating. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.